Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 131

1.

Combined blockade of activating ERBB2 mutations and ER results in synthetic lethality of ER+/HER2 mutant breast cancer.

Croessmann S, Formisano L, Kinch L, Gonzalez-Ericsson PI, Sudhan DR, Nagy RJ, Mathew A, Bernicker EH, Cristofanilli M, He J, Cutler RE, Lalani AS, Miller VA, Lanman RB, Grishin N, Arteaga CL.

Clin Cancer Res. 2018 Oct 12. pii: clincanres.1544.2018. doi: 10.1158/1078-0432.CCR-18-1544. [Epub ahead of print]

PMID:
30314968
2.

Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).

Cocco E, Javier Carmona F, Razavi P, Won HH, Cai Y, Rossi V, Chan C, Cownie J, Soong J, Toska E, Shifman SG, Sarotto I, Savas P, Wick MJ, Papadopoulos KP, Moriarty A, Cutler RE Jr, Avogadri-Connors F, Lalani AS, Bryce RP, Chandarlapaty S, Hyman DM, Solit DB, Boni V, Loi S, Baselga J, Berger MF, Montemurro F, Scaltriti M.

Sci Signal. 2018 Oct 9;11(551). pii: eaat9773. doi: 10.1126/scisignal.aat9773.

PMID:
30301790
3.

Extended adjuvant therapy with neratinib plus fulvestrant blocks ER/HER2 crosstalk and maintains complete responses of ER+/HER2+ breast cancers: Implications to the ExteNET trial.

Sudhan DR, Schwarz LJ, Guerrero-Zotano A, Formisano L, Nixon MJ, Croessmann S, Gonzalez-Ericsson PI, Sanders M, Balko JM, Avogadri-Connors F, Cutler RE, Lalani AS, Bryce R, Auerbach A, Arteaga CL.

Clin Cancer Res. 2018 Oct 1. pii: clincanres.1131.2018. doi: 10.1158/1078-0432.CCR-18-1131. [Epub ahead of print]

PMID:
30274983
4.

Neratinib augments the lethality of [regorafenib + sildenafil].

Booth L, Roberts JL, Rais R, Cutler RE Jr, Diala I, Lalani AS, Hancock JF, Poklepovic A, Dent P.

J Cell Physiol. 2018 Sep 10. doi: 10.1002/jcp.27276. [Epub ahead of print]

PMID:
30203445
5.

Palbociclib augments Neratinib killing of tumor cells that is further enhanced by HDAC inhibition.

Booth L, Roberts JL, Rais R, Cutler RE Jr, Diala I, Lalani AS, Poklepovic A, Dent P.

Cancer Biol Ther. 2018 Sep 5:1-12. doi: 10.1080/15384047.2018.1507665. [Epub ahead of print]

PMID:
30183517
6.

Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.

Ribas R, Pancholi S, Rani A, Schuster E, Guest SK, Nikitorowicz-Buniak J, Simigdala N, Thornhill A, Avogadri-Connors F, Cutler RE Jr, Lalani AS, Dowsett M, Johnston SR, Martin LA.

Breast Cancer Res. 2018 Jun 8;20(1):44. doi: 10.1186/s13058-018-0983-1.

7.

[Neratinib + Valproate] exposure permanently reduces ERBB1 and RAS expression in 4T1 mammary tumors and enhances M1 macrophage infiltration.

Booth L, Roberts JL, Rais R, Kirkwood J, Avogadri-Connors F, Cutler RE Jr, Lalani AS, Poklepovic A, Dent P.

Oncotarget. 2017 Dec 26;9(5):6062-6074. doi: 10.18632/oncotarget.23681. eCollection 2018 Jan 19.

8.

HER kinase inhibition in patients with HER2- and HER3-mutant cancers.

Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn DI, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, Erinjeri JP, Scaltriti M, Ulaner GA, Patel J, Tang J, Beer H, Selcuklu SD, Hanrahan AJ, Bouvier N, Melcer M, Murali R, Schram AM, Smyth LM, Jhaveri K, Li BT, Drilon A, Harding JJ, Iyer G, Taylor BS, Berger MF, Cutler RE Jr, Xu F, Butturini A, Eli LD, Mann G, Farrell C, Lalani AS, Bryce RP, Arteaga CL, Meric-Bernstam F, Baselga J, Solit DB.

Nature. 2018 Feb 8;554(7691):189-194. doi: 10.1038/nature25475. Epub 2018 Jan 31.

9.

The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells.

Booth L, Roberts JL, Samuel P, Avogadri-Connors F, Cutler RE, Lalani AS, Poklepovic A, Dent P.

Cancer Biol Ther. 2018 Jun 3;19(6):525-533. doi: 10.1080/15384047.2018.1436024. Epub 2018 Mar 6.

PMID:
29405820
10.

The irreversible ERBB1/2/4 inhibitor neratinib interacts with the BCL-2 inhibitor venetoclax to kill mammary cancer cells.

Booth L, Roberts JL, Avogadri-Connors F, Cutler RE Jr, Lalani AS, Poklepovic A, Dent P.

Cancer Biol Ther. 2018 Mar 4;19(3):239-247. doi: 10.1080/15384047.2018.1423927. Epub 2018 Jan 22.

PMID:
29333953
11.

The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib.

Booth L, Roberts JL, Poklepovic A, Kirkwood J, Sander C, Avogadri-Connors F, Cutler RE Jr, Lalani AS, Dent P.

Cancer Biol Ther. 2018 Feb 1;19(2):132-137. doi: 10.1080/15384047.2017.1394556. Epub 2017 Dec 8.

12.

HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo.

Booth L, Roberts JL, Poklepovic A, Avogadri-Connors F, Cutler RE, Lalani AS, Dent P.

Oncotarget. 2017 Oct 9;8(52):90262-90277. doi: 10.18632/oncotarget.21660. eCollection 2017 Oct 27.

13.

An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer.

Hanker AB, Brewer MR, Sheehan JH, Koch JP, Sliwoski GR, Nagy R, Lanman R, Berger MF, Hyman DM, Solit DB, He J, Miller V, Cutler RE Jr, Lalani AS, Cross D, Lovly CM, Meiler J, Arteaga CL.

Cancer Discov. 2017 Jun;7(6):575-585. doi: 10.1158/2159-8290.CD-16-1431. Epub 2017 Mar 8.

14.

A phase I/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumors.

Papadopoulos KP, Burris HA 3rd, Gordon M, Lee P, Sausville EA, Rosen PJ, Patnaik A, Cutler RE Jr, Wang Z, Lee S, Jones SF, Infante JR.

Cancer Chemother Pharmacol. 2013 Oct;72(4):861-8. doi: 10.1007/s00280-013-2267-x. Epub 2013 Aug 25.

15.

EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.

Trowe T, Boukouvala S, Calkins K, Cutler RE Jr, Fong R, Funke R, Gendreau SB, Kim YD, Miller N, Woolfrey JR, Vysotskaia V, Yang JP, Gerritsen ME, Matthews DJ, Lamb P, Heuer TS.

Clin Cancer Res. 2008 Apr 15;14(8):2465-75. doi: 10.1158/1078-0432.CCR-07-4367.

16.

Stk10, a new member of the polo-like kinase kinase family highly expressed in hematopoietic tissue.

Walter SA, Cutler RE Jr, Martinez R, Gishizky M, Hill RJ.

J Biol Chem. 2003 May 16;278(20):18221-8. Epub 2003 Mar 13.

17.

Regulation of PKC delta expression by estrogen and rat placental lactogen-1 in luteinized rat ovarian granulosa cells.

Peters CA, Cutler RE, Maizels ET, Robertson MC, Shiu RP, Fields P, Hunzicker-Dunn M.

Mol Cell Endocrinol. 2000 Apr 25;162(1-2):181-91.

PMID:
10854711
18.

Identification of cAMP-dependent protein kinase holoenzymes in preantral- and preovulatory-follicle-enriched ovaries, and their association with A-kinase-anchoring proteins.

Carr DW, Cutler RE Jr, Cottom JE, Salvador LM, Fraser ID, Scott JD, Hunzicker-Dunn M.

Biochem J. 1999 Dec 1;344 Pt 2:613-23.

19.

Regulation of protein kinase C delta by estrogen in the MCF-7 human breast cancer cell line.

Shanmugam M, Krett NL, Maizels ET, Cutler RE Jr, Peters CA, Smith LM, O'Brien ML, Park-Sarge OK, Rosen ST, Hunzicker-Dunn M.

Mol Cell Endocrinol. 1999 Feb 25;148(1-2):109-18.

PMID:
10221776
20.

Identification of residues in the cysteine-rich domain of Raf-1 that control Ras binding and Raf-1 activity.

Winkler DG, Cutler RE Jr, Drugan JK, Campbell S, Morrison DK, Cooper JA.

J Biol Chem. 1998 Aug 21;273(34):21578-84.

21.

Autoregulation of the Raf-1 serine/threonine kinase.

Cutler RE Jr, Stephens RM, Saracino MR, Morrison DK.

Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9214-9.

22.

Heat-shock protein-25/27 phosphorylation by the delta isoform of protein kinase C.

Maizels ET, Peters CA, Kline M, Cutler RE Jr, Shanmugam M, Hunzicker-Dunn M.

Biochem J. 1998 Jun 15;332 ( Pt 3):703-12. Erratum in: Biochem J. 2003 Feb;33(3):605..

23.

The Familial Cancer Program of the Vermont Cancer Center: Development of a Cancer Genetics Program in a Rural Area.

McKinnon WC, Guttmacher AE, Greenblatt MS, Compas BE, May S, Cutler RE, Yandell DW.

J Genet Couns. 1997 Jun;6(2):131-45. doi: 10.1023/A:1025603900839.

PMID:
26142091
25.
26.

The complexity of Raf-1 regulation.

Morrison DK, Cutler RE.

Curr Opin Cell Biol. 1997 Apr;9(2):174-9. Review.

PMID:
9069260
27.

Human plasma concentrations of R, S, and racemic flurbiprofen given as a toothpaste.

Forland SC, Wechter WJ, Witchwoot S, Clifford KH, Arnett RL, Cutler RE.

J Clin Pharmacol. 1996 Jun;36(6):546-53.

PMID:
8809639
28.

Delta protein kinase-C in the rat ovary: estrogen regulation and localization.

Cutler RE Jr, Maizels ET, Hunzicker-Dunn M.

Endocrinology. 1994 Oct;135(4):1669-78.

PMID:
7925131
29.

Regulation of delta protein kinase C during rat ovarian differentiation.

Cutler RE Jr, Maizels ET, Brooks EJ, Mizuno K, Ohno S, Hunzicker-Dunn M.

Biochim Biophys Acta. 1993 Nov 24;1179(3):260-70.

PMID:
8218370
30.
31.

cAMP-dependent protein kinases in the rat testis: regulatory and catalytic subunit associations.

Weiss J, DeManno DA, Cutler RE Jr, Brooks EJ, Erlichman J, Sanwal BD, Hunzicker-Dunn M.

Biochim Biophys Acta. 1992 Aug 12;1136(2):208-18.

PMID:
1504106
32.
33.

Isozymes of cAMP-dependent protein kinase present in the rat corpus luteum.

Hunzicker-Dunn M, Cutler RE Jr, Maizels ET, DeManno DA, Lamm ML, Erlichman J, Sanwal BD, LaBarbera AR.

J Biol Chem. 1991 Apr 15;266(11):7166-75.

34.

The pharmacokinetics and colonic tissue concentrations of cyclosporine after i.v., oral, and enema administration.

Sandborn WJ, Strong RM, Forland SC, Chase RE, Cutler RE.

J Clin Pharmacol. 1991 Jan;31(1):76-80.

PMID:
2045532
35.

Calcium-independent phospholipid/diolein-dependent phosphorylation of a soluble ovarian Mr 80,000 substrate protein: biochemical characteristics.

Maizels ET, Miller JB, Cutler RE Jr, Jackiw V, Carney EM, Kern L, Hunzicker-Dunn M.

Biochim Biophys Acta. 1990 Sep 24;1054(3):285-96.

PMID:
1698459
36.

Single-dose effects of ibopamine hydrochloride on renal function in patients with congestive heart failure.

Kasmer RJ, Cutler RE, Munger MA, Jarvis RC, Hricik D, Nara AR, Goldberg P, Green JA.

Br J Clin Pharmacol. 1990 Sep;30(3):485-9.

37.

Pharmacokinetics and pharmacodynamics of oral and intravenous cimetidine in seriously ill patients.

Sandborn WJ, Forland SC, Cutler RE, Strong RM.

J Clin Pharmacol. 1990 Jun;30(6):568-71.

PMID:
2355107
38.

Apparent reduced absorption of gemfibrozil when given with colestipol.

Forland SC, Feng Y, Cutler RE.

J Clin Pharmacol. 1990 Jan;30(1):29-32.

PMID:
2303577
40.

The effects of renal function on the disposition of isradipine.

Chandler MH, Schran HF, Cutler RE, Smith AJ, Gonasun LM, Blouin RA.

J Clin Pharmacol. 1988 Dec;28(12):1076-80.

PMID:
2977394
42.

Pharmacokinetics of iothalamate in endstage renal disease.

Evans JR, Cutler RE, Forland SC.

J Clin Pharmacol. 1988 Sep;28(9):826-30.

PMID:
3230149
43.

Flecainide pharmacokinetics after multiple dosing in patients with impaired renal function.

Forland SC, Cutler RE, McQuinn RL, Kvam DC, Miller AM, Conard GJ, Parish S.

J Clin Pharmacol. 1988 Aug;28(8):727-35.

PMID:
3145942
44.

Oral flecainide pharmacokinetics in patients with impaired renal function.

Forland SC, Burgess E, Blair AD, Cutler RE, Kvam DC, Weeks CE, Fox JM, Conard GJ.

J Clin Pharmacol. 1988 Mar;28(3):259-67.

PMID:
3129455
45.

The effect of renal function on the pharmacokinetics of gemfibrozil.

Evans JR, Forland SC, Cutler RE.

J Clin Pharmacol. 1987 Dec;27(12):994-1000.

PMID:
3481387
46.

Effects of a magnesium-free dialysate on magnesium metabolism during continuous ambulatory peritoneal dialysis.

Shah GM, Winer RL, Cutler RE, Arieff AI, Goodman WG, Lacher JW, Schoenfeld PY, Coburn JW, Horowitz AM.

Am J Kidney Dis. 1987 Oct;10(4):268-75.

PMID:
3661548
47.

Assay of gemfibrozil in plasma by "high-performance" liquid chromatography.

Forland SC, Chaplin L, Cutler RE.

Clin Chem. 1987 Oct;33(10):1938. No abstract available.

PMID:
3478157
48.

Low osmolar contrast agents and nephrotoxicity.

Evans JR, Shankel SW, Cutler RE.

Ann Intern Med. 1987 Jul;107(1):116. No abstract available.

PMID:
3592430
49.

Antihypertensive therapy in the elderly. Effects on blood pressure and cerebral blood flow.

Ram CV, Meese R, Kaplan NM, Devous MD Sr, Bonte FJ, Forland SC, Cutler RE.

Am J Med. 1987 Jan 5;82(1A):53-7.

PMID:
3799702
50.

Reappraisal of femoral vein cannulation for temporary hemodialysis vascular access.

Firek AF, Cutler RE, St John Hammond PG.

Nephron. 1987;47(3):227-8. No abstract available.

Supplemental Content

Loading ...
Support Center